Oncolytics Biotech Inc Total Assets
Oncolytics Biotech Inc total assets. Based on the latest financial reports, Oncolytics Biotech Inc (ONC) holds total assets worth CA$19.97 Million CAD (≈ $14.45 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Oncolytics Biotech Inc for the company's overall valuation and market capitalisation.
Total Assets of Oncolytics Biotech Inc (1999–2024)
Total assets of Oncolytics Biotech Inc from 1999 to 2024. This chart illustrates how Oncolytics Biotech Inc's total assets have evolved over time, based on quarterly financial data. See latest Oncolytics Biotech Inc stock price today for real-time trading data and today's change.
Oncolytics Biotech Inc - Asset Composition Analysis
Oncolytics Biotech Inc Total Assets Breakdown (December 2024)
Oncolytics Biotech Inc total assets breakdown as of December 2024. Oncolytics Biotech Inc's total assets of CA$19.97 Million consist of 93.5% current assets and 6.5% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$3.63 Million | 79.0% |
| Accounts Receivable | CA$0.00 | 0.0% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$1.31 Million | 6.5% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (1999–2024)
This chart illustrates how Oncolytics Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Oncolytics Biotech Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncolytics Biotech Inc's current assets represent 93.5% of total assets in 2024, an increase from 64.0% in 1999.
- Cash Position: Cash and equivalents constituted 79.0% of total assets in 2024, up from 63.5% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 35.0% in 1999.
- Asset Diversification: The largest asset category is cash and equivalents at 79.0% of total assets.
Oncolytics Biotech Inc Competitors by Total Assets
Key competitors of Oncolytics Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Oncolytics Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.88 | 4.99 | 9.09 |
| Quick Ratio | 2.88 | 4.99 | 9.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$12.34 Million | CA$24.50 Million | CA$27.16 Million |
Oncolytics Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Oncolytics Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 23.41 |
| Latest Market Cap to Assets Ratio | 7.06 |
| Asset Growth Rate (YoY) | -48.0% |
| Total Assets | CA$20.19 Million |
| Market Capitalization | $142.51 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Oncolytics Biotech Inc's assets at a significant premium (7.06x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Oncolytics Biotech Inc's assets decreased by 48.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncolytics Biotech Inc (1999–2024)
The table below shows the annual total assets of Oncolytics Biotech Inc from 1999 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$20.19 Million ≈ $14.60 Million |
-48.00% |
| 2023-12-31 | CA$38.82 Million ≈ $28.08 Million |
+3.98% |
| 2022-12-31 | CA$37.33 Million ≈ $27.01 Million |
-18.63% |
| 2021-12-31 | CA$45.88 Million ≈ $33.19 Million |
+33.58% |
| 2020-12-31 | CA$34.35 Million ≈ $24.85 Million |
+74.72% |
| 2019-12-31 | CA$19.66 Million ≈ $14.22 Million |
+32.24% |
| 2018-12-31 | CA$14.87 Million ≈ $10.75 Million |
-18.10% |
| 2017-12-31 | CA$18.15 Million ≈ $13.13 Million |
+22.98% |
| 2016-12-31 | CA$14.76 Million ≈ $10.68 Million |
-46.11% |
| 2015-12-31 | CA$27.38 Million ≈ $19.81 Million |
+59.27% |
| 2014-12-31 | CA$17.19 Million ≈ $12.44 Million |
-39.08% |
| 2013-12-31 | CA$28.22 Million ≈ $20.42 Million |
+27.83% |
| 2012-12-31 | CA$22.08 Million ≈ $15.97 Million |
-38.71% |
| 2011-12-31 | CA$36.02 Million ≈ $26.06 Million |
-18.92% |
| 2010-12-31 | CA$44.43 Million ≈ $32.14 Million |
+19.22% |
| 2009-12-31 | CA$37.27 Million ≈ $26.96 Million |
+166.46% |
| 2008-12-31 | CA$13.99 Million ≈ $10.12 Million |
-54.56% |
| 2007-12-31 | CA$30.78 Million ≈ $22.27 Million |
-8.29% |
| 2006-12-31 | CA$33.57 Million ≈ $24.28 Million |
-27.50% |
| 2005-12-31 | CA$46.29 Million ≈ $33.49 Million |
+17.23% |
| 2004-12-31 | CA$39.49 Million ≈ $28.57 Million |
+51.58% |
| 2003-12-31 | CA$26.05 Million ≈ $18.84 Million |
+44.98% |
| 2002-12-31 | CA$17.97 Million ≈ $13.00 Million |
-5.79% |
| 2001-12-31 | CA$19.07 Million ≈ $13.80 Million |
-11.94% |
| 2000-12-31 | CA$21.66 Million ≈ $15.67 Million |
+202.33% |
| 1999-12-31 | CA$7.16 Million ≈ $5.18 Million |
-- |
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more